256 related articles for article (PubMed ID: 32892677)
1. Engineered Fc-glycosylation switch to eliminate antibody effector function.
Zhou Q; Jaworski J; Zhou Y; Valente D; Cotton J; Honey D; Boudanova E; Beninga J; Rao E; Wei R; Mauriac C; Pan C; Park A; Qiu H
MAbs; 2020; 12(1):1814583. PubMed ID: 32892677
[TBL] [Abstract][Full Text] [Related]
2. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
3. Fc-engineered antibodies with immune effector functions completely abolished.
Wilkinson I; Anderson S; Fry J; Julien LA; Neville D; Qureshi O; Watts G; Hale G
PLoS One; 2021; 16(12):e0260954. PubMed ID: 34932587
[TBL] [Abstract][Full Text] [Related]
4. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
6. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
7. Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.
Elter A; Yanakieva D; Fiebig D; Hallstein K; Becker S; Betz U; Kolmar H
Front Immunol; 2021; 12():715719. PubMed ID: 34413859
[TBL] [Abstract][Full Text] [Related]
8. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
9. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
[TBL] [Abstract][Full Text] [Related]
10. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
11. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
[TBL] [Abstract][Full Text] [Related]
12. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
13. Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments.
Mi W; Wanjie S; Lo ST; Gan Z; Pickl-Herk B; Ober RJ; Ward ES
J Immunol; 2008 Dec; 181(11):7550-61. PubMed ID: 19017944
[TBL] [Abstract][Full Text] [Related]
14. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
15. Engineering IgG1 Fc Domains That Activate the Complement System.
Lee CH; Delidakis G
Methods Mol Biol; 2022; 2421():187-200. PubMed ID: 34870820
[TBL] [Abstract][Full Text] [Related]
16. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
Kellner C; Derer S; Klausz K; Rosskopf S; Wirt T; Rösner T; Otte A; Cappuzzello E; Peipp M
Methods Mol Biol; 2018; 1827():381-397. PubMed ID: 30196508
[TBL] [Abstract][Full Text] [Related]
17. The Dual Targeting of FcRn and FcγRs
Monnet C; Jacque E; de Romeuf C; Fontayne A; Abache T; Fournier N; Dupont G; Derache D; Engrand A; Bauduin A; Terrier A; Seifert A; Beghin C; Longue A; Masiello N; Danino L; Nogre M; Raia A; Dhainaut F; Fauconnier L; Togbe D; Reitinger C; Nimmerjahn F; Stevens W; Chtourou S; Mondon P
Front Immunol; 2021; 12():728322. PubMed ID: 34512662
[TBL] [Abstract][Full Text] [Related]
18. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
19. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.
Moore GL; Chen H; Karki S; Lazar GA
MAbs; 2010; 2(2):181-9. PubMed ID: 20150767
[TBL] [Abstract][Full Text] [Related]
20. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.
van Erp EA; Luytjes W; Ferwerda G; van Kasteren PB
Front Immunol; 2019; 10():548. PubMed ID: 30967872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]